Anticancer drug | Dosagea (min ~ max) | Urinary unchanged drug excretion rate (% of dosage/24h)b | Urinary unchanged drug concentrationc (μg/mL) | Dripping concentration (μg/mL) | |
---|---|---|---|---|---|
Alkylating drug | CPA | 500mg/m2 – 60mg/kg | 10.0 | 50.0 – 201.2 | 2,000 |
IFM | 0.8 – 3g/m2 | 6.0 | 48.0 – 180.0 | 1,000 | |
Platinum drug | CBDCA | 300 – 635mg/m2 | 57.0 – 82.0 | 171.0 – 520.7 | 5,000 |
CDDP | 10 – 100mg/m2 | 14.0 – 54.0 | 1.4 – 54.0 | 100 | |
Antimetabolite drug | MTX | 10mg/body – 300mg/kg | 75.0 – 98.0(72h) | 1.4 – 3285.5 | 6,000 |
5-FU | 5mg/kg – 2600mg/m2 | 10.0 | 16.8 – 260 | 1,000 | |
Ara-C | 0.8mg/kg – 3,000mg/m2 | 7.1 – 7.8 | 1.9 – 234 | 1,000 | |
GEM | 1,000 – 1,250mg/m2 | 5.3 | 53.0 – 66.3 | 300 | |
Anthracycline drug | ADR | 0.2mg/kg – 80mg/m2 | 11.5 | 0.8 – 9.2 | 1,000 |
Epi-ADR | 15 – 100mg/m2 | 6.2 (48h) | 0.5 – 3.0 | 1,000 | |
Taxane drug | PTX | 80 – 210mg/m2 | 7.3 – 11.3(72h) | 1.9 – 7.9 | 200 |
DTX | 60 – 75mg/m2 | 1.7 – 4.2 (48h) | 0.5 – 1.6 | 200 | |
Topoisomerase inhibitor | VP-16 | 60 – 500mg/m2 | 10.3 – 35.2 | 6.2 – 176.0 | 500 |
CPT-11 | 20 – 180mg/m2 | 16.3 – 21.1 | 3.3 – 38.0 | 1,500 |